解郁丸与丁螺环酮治疗广泛性焦虑症疗效对照研究  

Control Study of Chinese Patent Medicin-jieyuwan and Buspirone in Treatment of Generalized Anxiety Disorder

作　　者：马建华[1] 李雅忠[1] 徐建国[1] 

机构地区：[1]中国.河北省唐山市第五医院,063004

出　　处：《中国健康心理学杂志》2009年第9期1034-1035,共2页China Journal of Health Psychology

摘　　要：目的验证中药解郁丸治疗广泛性焦虑症的临床疗效及副反应。方法采用随机、对照方法,共纳入中药解郁丸和丁螺环酮对照组各60例,于治疗前和疗后2、4、6周分别采用Hamilton焦虑量表(HAMA)、TESS副反应量表进行疗效与副反应评定,于疗程结束后采用4级疗效标准评定总体疗效。结果解郁丸组显效率80%,丁罗环酮组显效率76.6%,治疗前后两组内减分率比较差异有显著性,治疗前后两组间减分率差别无显著性。结论解郁丸治疗广泛性焦虑症的临床疗效肯定,与丁螺环酮疗效相当,且无明显副反应。Objective To test tiee efficacy and adverse effect of a new Chinese patent medicine-jieyuwan in treatment of general- ized anxiety disorder. Methods Jieyuwan therapy group and Buspirone controled group both enrolled 60 cases by randomized con- trol method. The efficacy and adverse effect were assessed by HAMA and.-TE~ before and after treatment,and the total efficacy $ was assessed by four criteria at the end of treatment. Results The effectiveness rate of Jieyuwan group was 80 percent and that of Buspirone group was 76.6 percent. The difference of sub-rate in the two groups was significant but that between the two groups was not significant before and after treatment. Conclusion The clinical efficacy of Jieyuwan to treat generalized anxiety disorder is affirmative and considerable with Buspirone with no apparent side effects.

关 键 词：解郁丸 丁罗环酮 广泛性焦虑症 临床观察 

分 类 号：R749.72[医药卫生—神经病学与精神病学] R749.3[医药卫生—临床医学]